SCHEMBL3397939

SCHEMBL3397939

Cc1ccccc1C(=O)NC(N)=S

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.60
RAB9A P51151 1/20 0.60
ALDH1A1 P00352 9/20 0.56
KDM4E B2RXH2 3/20 0.56
POLB P06746 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
HPGD P15428 3/20 0.54
ALOX12 P18054 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.54
LMNA P02545 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
MEN1 O00255 2/20 0.51
HTT P42858 2/20 0.51
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14907043 0.85 CA1 (0.66) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL4762283 0.85 HPGD (0.61) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL3140037 0.84 HPGD (0.64) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL6651792 0.81 HPGD (0.53) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL30320291 0.81 HPGD (0.53) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL29231950 0.80 HPGD (0.66) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL16358867 0.79 CA1 (0.73) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL29191662 0.79 SMN1; SMN2 (0.62) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL9818531 0.78 ALDH1A1 (0.77) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL12903506 0.78 ALDH1A1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114656423-A Preparation method of 4-methyl-2-hydrazinobenzothiazole hydrochloride 浙江南郊化学有限公司 2022-06-24 CN claimed
CN-111333593-B Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2022-04-29 CN claimed
CN-111333593-A Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2020-06-26 CN claimed
CN-114656423-A Preparation method of 4-methyl-2-hydrazinobenzothiazole hydrochloride 浙江南郊化学有限公司 2022-06-24 CN disclosed
CN-114656423-A Preparation method of 4-methyl-2-hydrazinobenzothiazole hydrochloride 浙江南郊化学有限公司 2022-06-24 CN disclosed
CN-111333593-B Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2022-04-29 CN disclosed
CN-111333593-B Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2022-04-29 CN disclosed
CN-211814216-U System for recycling o-toluidine in waste liquid generated in preparation of N-o-tolylthiourea 山西瑞赛科环保科技有限公司 2020-10-30 CN disclosed
CN-111333593-A Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2020-06-26 CN disclosed
CN-111333593-A Method for synthesizing 4-methyl-2 hydrazinobenzothiazole 湖北可赛化工有限公司 2020-06-26 CN disclosed
CN-101129295-B There is the binary initiator system of good storage stability and especially suitable for acidic system HERAEUS KULZER GMBH (DE) 2016-02-10 CN disclosed
WO-2011022393-A2 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN INHIBITORS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2011-02-24 WO disclosed
US-20100324096-A1 Whitening Agent And Skin External Preparation SHISEIDO COMPANY LTD. (JP) 2010-12-23 US disclosed
EP-2251001-A1 SKIN WHITENING AGENT AND EXTERNAL PREPARATION FOR THE SKIN Shiseido Company, Ltd. (JP) 2010-11-17 EP disclosed
CN-101129295-A 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems HERAEUS KULZER GMBH (DE) 2008-02-27 CN disclosed
CN-85109721-A Preparation has the ectoparasite of the no disease homoiothermic animal of control and the method for endoparasite compositions 1987-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324096-A1 Whitening Agent And Skin External Preparation TYR, MC1R, PAH NPC1 3805/4885RAB9A 2964/4885ALDH1A1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.